1. Oncol Ther. 2019 Dec;7(2):121-130. doi: 10.1007/s40487-019-0095-9. Epub 2019
May  22.

Efficacy of All-Trans-Retinoic Acid in High-Risk Acute Myeloid Leukemia with 
Overexpression of EVI1.

Paubelle E(1)(2)(3), Plesa A(4), Hayette S(4), Elhamri M(1), Zylbersztejn F(5), 
Hermine O(5)(6), Salles G(1), Thomas X(7).

Author information:
(1)Department of Clinical Hematology, Hospices Civils de Lyon, Centre 
Hospitalier Lyon-Sud, Pierre Bénite, France.
(2)Faculté de Médecine Lyon-Sud Charles Mérieux, Université de Lyon, Pierre 
Bénite, France.
(3)Laboratoire de Biologie et Modélisation de la Cellule, CNRS UMR5239, Faculté 
de Médecine Lyon-Sud, Ecole Normale supérieure de Lyon, Hospices Civils de Lyon, 
Pierre Bénite, France.
(4)Department of Biological Hematology, Hospices Civils de Lyon, Centre 
Hospitalier Lyon-Sud, Pierre-Bénite, France.
(5)Laboratory of Molecular Mechanisms of Hematologic Disorders and Therapeutic 
Implications, Imagine Institute, Paris, France.
(6)Department of Clinical Hematology, Hôpital Necker-Enfants-Malades, Paris, 
France.
(7)Department of Clinical Hematology, Hospices Civils de Lyon, Centre 
Hospitalier Lyon-Sud, Pierre Bénite, France. xavier.thomas@chu-lyon.fr.

INTRODUCTION: EVI1 (MECOM)-positive acute myeloid leukemia (AML) cells have 
shown in vitro sensitivity to all-trans-retinoic acid (ATRA) by inducing 
differentiation, cell death, and decreased leukemic engraftment.
METHODS: In this pilot study, we investigated the response to ATRA in 13 
high-risk AML patients with overexpression of EVI1.
RESULTS: Seven of the 13 patients (53.8%) achieved complete remission (CR), and 
response can be combined with a decreased of the leukemia stem cell pool.
CONCLUSION: These primary results tend to confirm in vitro results and suggest 
that addition of ATRA might be of benefit in the treatment of patients with 
EVI1-positive AML.

DOI: 10.1007/s40487-019-0095-9
PMCID: PMC7359977
PMID: 32699982